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Treating cancer with vaccines has been a challenging ﬁeld of investigation since the 1950s. Over the years, the lack of eﬀective
active immunotherapies has led to the development of numerous novel strategies. However, the use of therapeutic cancer vaccines
may be on the verge of becoming an eﬀective modality. Recent phase II/III clinical trials have achieved hopeful results in terms of
overallsurvival.Yetdespitetheseencouragingsuccesses,ingeneral,verylittleisknownaboutthebasicimmunologicalmechanisms
involvedinvaccineimmunotherapy.Gainingabetterunderstandingofthemechanismsthatgovernthespeciﬁcimmuneresponses
(i.e., cytotoxic T lymphocytes, CD4 T helper cells, T regulatory cells, cells of innate immunity, tumor escape mechanisms) elicited
by each of the various vaccine platforms should be a concern of cancer vaccine clinical trials, along with clinical beneﬁts. This
review focuses on current strategies employed by recent clinical trials of therapeutic cancer vaccines and analyzes them both
clinically and immunologically.
1.Introduction
Cancer is the second leading cause of death in the United
States, exceeded only by heart disease (23.1% versus 26.0%
of total deaths, resp.). Currently, 1 in 4 deaths in the United
Statesisduetocancer.AccordingtoAmericanCancerSociety
statistics, an estimated 1,479,350 new cases and 562,340
deaths from cancer are expected during 2009, with a slightly
higher incidence and death rate in the male population.
Prostate, lung, and colorectal cancers are the most common
types of cancer in men; breast, lung, and colorectal cancers
are most common among women. Altogether, lung, breast,
prostate, and colorectal cancers account for 49% of cancer-
related deaths in the U.S. population [1]. Overall, except for
lung cancer in women, incidence and mortality rates have
steadily decreased for all 4 types of cancer in both men and
women, probably due to both an increase in early diagnosis
and improvements in therapy and combination therapies
(surgery, radiotherapy, chemotherapy, and, lately, targeted
therapy). But despite these encouraging advances, cancer is
still a major public health problem worldwide, requiring
new strategies and treatment modalities to optimize patient
outcomes.
In this context, immunotherapy has always been an
attractive and potentially eﬃcient treatment for cancer
patients [19]. Tumor immunotherapy can generally be
classiﬁed as (a) passive (or adaptive), consisting of admin-
istration of cells or antibodies ex vivo, and (b) active,
represented by vaccines, aimed at eliciting a speciﬁc
immune response against tumor-speciﬁc antigens (TSAs)
and tumor-associated antigens (TAAs). Prophylactic and
therapeutic vaccines represent one of the most intriguing
approaches in the multidisciplinary treatment of cancer
patients.Comparedtoallotherstandardmodalities(surgery,
chemotherapy, radiotherapy, and adaptive immunotherapy),
an eﬀective vaccine-based immune response against tumor
may be the only cancer treatment with the potential to last
a lifetime. Theoretically, vaccinated patients could mount
an immune response able to either cure tumor or keep
it under constant restraint (i.e., immune surveillance),
delaying tumor recurrence and prolonging survival.
One of the major problems in developing an eﬃcient
cancer vaccine is the lack of TSAs and the weakness of
immune responses against TAAs, usually recognized by the
immune system as self-antigens. During the last decades,
various strategies for therapeutic cancer vaccines have been2 Journal of Biomedicine and Biotechnology
proposed to overcome this weak immune response against
TAAs, including cell-based vaccines, DNA- or RNA-based
vaccines, protein- or peptide-based vaccines, and vector-
based vaccines [20]. The common rationale for all these
modalities is the activation of antigen-presenting cells
(APCs)andthestimulationofanantigen-speciﬁccytotoxicT
lymphocyte-(CTL-) mediated immune response. Dendritic
cells (DCs) are the most potent APCs, and various strategies
have been used to enhance their ability to activate T cells.
This review focuses on the state of the art of these modalities
and analyzes the most promising phase II/III clinical trials,
emphasizing vaccines directed against carcinomas (Table 1).
Despite recent achievements, one criticism of some of these
clinical trials has been the lack of immunological data sup-
porting the signiﬁcant improvements in time to progression
and overall survival (OS) observed. An eﬀort should be
made to deﬁne the speciﬁc components of each immune
response as a consequence of anticancer vaccination. In
this context, both the speciﬁcity and the identiﬁcation of
potential escape mechanisms (i.e., increase of Treg number
or function, balance between positive and negative regu-
lators of antitumor responses, such as CD28, cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4), programmed
death-1 molecule (PD-1) and its ligands PD-L1 and PD-
L2) should be investigated. Increasing our understanding of
how these modalities modulate the CTL response is vital to
developing novel and eﬀective antitumor vaccines.
The goal of therapeutic cancer vaccines is to “teach” the
patient’s own immune system to speciﬁcally recognize and
eliminate tumor cells. The potential target for the immune
response can be either TSAs (antigens present only on tumor
cells) or TAAs (antigens present mostly on tumor cells but
also on some normal cells). Theoretically, TSAs are the ideal
target for cancer immunotherapy because of their speciﬁcity.
They are largely composed of mutant proteins caused by
somatic mutations in the original sequence of the protein.
A major advantage of targeting TSAs is that many of these
proteins have been demonstrated to be essential for tumori-
genesis and cancer progression [21]. On the other hand, a
major drawback of targeting TSAs is the fact that most of the
mutations identiﬁed are unique to each tumor, potentially
requiring the development of personalized immunotherapy
for individual patients. In contrast, TAAs are commonly
expressed on tumors with the same histology and are shared
among tumors of diﬀerent origin. A major limitation of
targeting TAAs is that they are weakly immunogenic due
to the tolerance for self-antigens acquired by the immune
system in its developmental stages [22].
In the last decades, several diﬀerent mechanisms have
been proposed to “instruct” DCs, the most potent APCs
known, to induce Th and CTL responses against tumor
antigens, thus breaking immune tolerance. Antigen-loading
techniques include (a) infecting DCs with viral, bacterial, or
yeast vectors, (b) pulsing DCs with proteins or peptides, (c)
loading DCs with tumor cells or tumor-cell lysates, and (d)
transfecting DCs with DNA or RNA (Figure 1)[ 20].
Encouraged by positive preclinical and clinical data
[23–27], further studies are currently ongoing to evaluate
the possibility to enhance vaccine-induced immunity by
combining vaccines with low doses of chemotherapeutic
agents (i.e., cyclophosphamide, doxorubicin, docetaxel) or
radiationtherapy,thatshowedsynergisticimmunotherapeu-
tic eﬀects when given in proper sequence.
2. Vaccines with Viral,Bacterial,
or Yeast Vectors
As mentioned above, one of the major diﬃculties in cancer
immunotherapy is to develop a strategy to overwhelm the
characteristically weak immune response of the host against
TAAs. Several vectors can be used to deliver recombi-
nant genes (including genes expressing TAAs, costimulatory
molecules, or cytokines) into APCs. Recombinant vector-
based vaccines may induce the immune system to generate
a strong inﬂammatory response, directed mainly towards
vectorproteins.Inturn,thisinﬂammatoryresponsemaylead
toanincreasedimmuneresponseagainstthegenesofinterest
that have been inserted into the vector. One advantage of
using vectors as vehicles for TAAs is that this type of delivery
of a recombinant protein is much more immunogenic than
administering the protein with adjuvants [28, 29].
Vectors used in cancer immunotherapy include viral,
bacterial, and yeast vectors. The choice of vector can
have important consequences for the subsequent immune
response against TAAs because each vector has its own
characteristics and is potentially able to uniquely stimulate
the host immune system. A further factor that must be
taken into account in the development of an eﬃcient
vector-based vaccine strategy is the balance between the
stimulation of innate versus adaptive responses, Th1 versus
Th2 responses, or the preferred activation of subsets of cells
mainly committed to regulatory (Tregs, Tr1, and Th3) or
proinﬂammatory functions (Th17).
Poxviral vectors are among the most heavily exploited
in vaccine development. The prototype is vaccinia virus,
which was used successfully to eradicate smallpox [30].
The poxvirus family is composed of double-stranded DNA
viruses that replicate within the cytoplasm of infected cells.
This feature is important for the safe use of poxviruses as
recombinant vaccines, since no genetic sequence from the
virus will be inserted into the host cell genome. However,
owing to concerns about the use of replicating vectors
in potentially immunocompromised patients and immune
responsesgeneratedagainstthevectorbyimmunocompetent
patients, developing safe, nonreplicating viral vectors has
been the focus of extensive research. Other attenuated
poxviruses have been identiﬁed and are currently available
for clinical use. Fowlpox, an avipoxvirus, can infect mam-
malian cells abortively, but recombinant-encoded genes are
transcribed [31]. The drawback is that recombinant fowlpox
usuallygeneratesaweakerimmuneresponseinhumansthan
vaccinia and is thus often used for booster vaccinations after
a primary vaccination with recombinant vaccinia. Modiﬁed
vaccinia Ankara (MVA) is a highly attenuated strain of
vaccinia that was developed by hundreds of passages of
vaccinia virus in chick embryo ﬁbroblasts. MVA can infect
mammalian cells and undergo DNA replication in themJournal of Biomedicine and Biotechnology 3
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Figure 1: Various modalities employing dendritic cells for the development of therapeutic cancer vaccines.
but has lost the ability to produce infective viral particles
[32]. Preclinical and clinical studies have demonstrated
the superiority of a priming vaccination with recombinant
vaccinia followed by multiple boosts with recombinant
fowlpox, over diﬀerent dosing schedules or the continuous
use of either vector alone [33–36].
The large genome of poxviruses (approximately 130kb
for mammalian poxviruses and 300kb for avian poxviruses)
allows for insertion of more than 10kb of foreign DNA.
Moreover, gene products are usually expressed at high
levels, resulting in a potent cellular immune response. As
mentioned previously, poxviruses can also be modiﬁed to
express one or more T-cell costimulatory molecules along
with the transgene for a TAA, or cytokines such as GM-
CSF. Tumor recognition by CTLs is a complex mechanism
that requires several diﬀerent signals. DCs provide T cells
with antigenic signal 1 through the speciﬁc interaction
betweenthepeptide-MHCIcomplexandtheT-cellreceptor.
A costimulatory signal 2 is needed for the activation and
expansion of T cells. Finally, DCs provide an additional
polarizing signal 3 through the release of diﬀerent cytokines,
driving the immune response toward type-1 or type-2
immunity. Therefore, costimulatory molecules are critical
in the generation of potent T-cell responses, particularly
toward weak antigens such as TAAs. The most studied
costimulatory signals involve the interaction between B7.1
(CD80) expressed on APCs and CD28 or CTLA-4 on T
cells, between intercellular adhesion molecule-1 (ICAM-1 or
CD54)onAPCsandleukocytefunction-associatedantigen-1
(LFA-1) on T cells, and between LFA-3 (CD58) on APCs and
CD2 on T cells [37].
PSA-TRICOM vaccine (prostate-speciﬁc antigen plus a
TRIad of COstimulatory Molecules; PROSTVAC) consists
of a priming vaccination with recombinant vaccinia- (rV-)
PSA-TRICOM and booster vaccinations with recombinant
fowlpox- (rF-) PSA-TRICOM. Each vaccine consists of the
transgenes for PSA, including an agonist epitope [38], and 3
immune costimulatory molecules (B7.1, ICAM-1, and LFA3;
designated TRICOM). The eﬃcacy of PSA-TRICOM has
been evaluated in 2 phase II clinical trials in patients with
metastatichormone-refractoryprostatecancer(mHRPC).In
the ﬁrst multicenter clinical trial, 122 patients with Gleason
scores of ≤ 7w e r er a n d o m i z e d2:1t or e c e i v eP S A - T R I C O M
plus GM-CSF (n = 82) versus an empty-vector placebo (n =
40). A vaccinia-based vector was used as prime, followed by
6 boosts with a fowlpox-based vector. Vaccinated patients
had a greater 3-year OS compared to the placebo arm (30%
versus 17%, resp.) and an improvement in median OS of 8.5
months (24.5 months versus 16 months, resp.; P = .016). T-
cell responses to vaccine or vector were not evaluated in this
trial [2–4].
In a concurrent phase II clinical trial at the National
Cancer Institute employing the identical PSA-TRICOM
vaccine, 32 patients (representing all Gleason scores) were4 Journal of Biomedicine and Biotechnology
Table 1: Overview of 4 diﬀerent vaccination strategies employed in clinical trials.
VACCINE PHASE TUMOR PTS∗ NOTE REF.
Vaccines with
viral vectors
PSA-TRICOM II Prostate 122
8.5 mos OS
improvement versus
placebo.
[2–4]
II Prostate 32
>16.4 mos OS
improvement in
HPS>18 mos group.
[5]
PANVAC-VF III Pancreatic 255
Failed >OS. Pts with
life expectancy <3
mos.
[6]
Vaccines with
peptides
Provenge III Prostate 512
4.1 mos OS
improvement versus
placebo.
[7, 8]
Oncophage III Melanoma 322
Prolonged OS in M1a
or M1b
subpopulation.
[9]
III Renal 818 No diﬀerence in DFS
and OS.
[10]
gp100:209-
217(210M)
III Melanoma 185
Signiﬁcant
improvement in RR
and PFS.
[11]
Stimuvax IIB Lung 171
17.3 mos OS
improvement versus
BSC in locoregional
stage IIIB.
[12]
Vaccines with
tumor cells or
tumor-cell
lysates
OncoVAX III Colon 254
Signiﬁcant
improvement in DFS
and OS in stage II.
[13–15]
Reniale III Renal 558
Signiﬁcant
improvement in DFS
and OS.
[16, 17]
GVAX III Prostate 626 Failed to improve OS
versus docetaxel.
[6]
III Prostate 408
Failed. Higher death
rate in combination
arm (vaccine +
docetaxel) versus
docetaxel alone.
[6]
Vaccines with
RNA
mRNA from
PCa cell lines
I/II Prostate 19 Immunological
responses.
[18]
∗PTS: patients enrolled.
randomized to 1 of 4 cohorts. Cohort 1 received no immune
adjuvant; cohort 2 received recombinant human GM-CSF
protein; cohort 3 received 107 plaque-forming units (pfu)
rF-GM-CSF; cohort 4 received 108 p f ur F - G M - C S F .A l l
patients were primed with rV-PSA-TRICOM s.c. on day
1 and then received monthly boosts of rF-PSA-TRICOM
until progression. Patients who remained on-study after 12
months had booster vaccinations every 3 months. With
a median follow-up of 44.6 months, the median OS for
all 32 patients on-study was 26.6 months, compared toJournal of Biomedicine and Biotechnology 5
a median Halabi nomogram-predicted survival of 17.4
months (an improvement of 9.2 months) [5]. No major
diﬀerences were observed among the 4 cohorts. The sub-
analysis of patients with a Halabi-predicted survival (HPS)
of <18 months showed a minimal diﬀerence between actual
OS and HPS. However, patients with HPS >18 months
had a signiﬁcant increase in actual OS (>37.3 months,
median not reached, with 8 of 15 patients still alive at 44.6
months) compared to HPS (20.9 months). PBMCs from
patients pre and post vaccination were analyzed by ELISPOT
assay to evaluate the speciﬁc immune response against the
HLA-A2 PSA peptide PSA-3 [39]. Thirteen of 29 patients
analyzed had an enhanced (≥2-fold) PSA-3-speciﬁc T-cell
immune response post vaccination. Furthermore, patients
with a postvaccination ELISPOT response to PSA epitope
>6-fold seemed to live longer, compared to patients with a
postvaccination ELISPOT response to PSA epitope <6-fold
(P = .055). We also analyzed Treg function pre and post
vaccination. Among patients who survived longer than pre-
dicted, Treg suppressive function decreased in 10/13 (77%)
after 3 vaccinations versus pre vaccination. In contrast,
among patients whose survival was less than predicted, Treg
function increased in 6/8 (75%) after 3 vaccinations versus
pre vaccination. These data strongly suggest that Tregs play
a signiﬁcant role in the modulation of antitumor immune
response [40].
PANVAC-VF, another poxviral-based vaccine, consists
of a priming vaccination with rV encoding CEA(6D),
MUC1(L93), and TRICOM plus booster vaccinations with
rF expressing the identical transgenes. CEA(6D) and
MUC1(L93) represent carcinoembryonic antigen and mucin
1 glycoprotein, respectively, with a single amino acid substi-
tution designed to enhance their immunogenicity [41, 42].
A phase III study in patients with advanced pancreatic
cancer treated with PANVAC-VF as second-line therapy
showed no improvement in survival [6]. The vaccine is
currently under evaluation in several diﬀerent types of CEA-
or MUC1-expressing carcinomas and in patients with a
life expectancy >3 months. In our experience, PANVAC-
VF was well tolerated in a pilot study enrolling 25 patients
with metastatic carcinomas. After vaccination, CAP1(6D)-
speciﬁcCD8immuneresponsesweredetectedin3/8patients
by ELISPOT, CAP1(6D)-tetramer, and intracellular IFN-
γ staining. We also evaluated CD4 immune responses in
15 patients included in the study, using CEA protein as
antigen. Six of 15 patients with undetectable levels of IFN-
γ pre vaccination showed measurable levels in response
to CEA protein. Four of 14 patients were positive for
the generation of MUC1-speciﬁc T cells post vaccination
[43].
T h er a t i o n a l ef o rt h eu s eo fm i c r o b e ss u c ha sy e a s ta s
delivery vehicles for TAAs is based on the ability of these
agents to activate a proinﬂammatory response through the
interaction of pathogen-associated molecular patterns with
pattern-recognition receptors, such as Toll-like receptors,
expressed on APCs. These interactions play a central role
in the activation of innate and adaptive immunity [44].
Over the years, several diﬀerent bacterial and yeast vectors,
such as Escherichia coli, Salmonella, Shigella, Yersinia, Listeria
monocytogenes,a n dSaccharomyces cerevisiae,h a v eb e e n
investigated for use as vaccine vectors.
The development of genetic engineering technology and
eﬃcient fermentation procedures has made large-scale, cost-
eﬀective production of these vectors possible and is one of
the major advantages of their use in antitumor vaccines.
Unfortunately, development of yeast-based vaccines has
laggedbehindthatofcell-,protein-,andviral-basedvaccines,
and clinical experience has been limited to phase I/II studies
[45]. One such vector currently being evaluated is a whole,
heat-killed, recombinant S. cerevisiae yeast (Tarmogens GI-
4000, GlobeImmune) intended to generate a T-cell response
to eliminate tumor cells expressing the 7 most common
mutations in the ras oncogene product. A randomized,
double-blind, placebo-controlled phase IIa clinical trial
has enrolled 100 patients with resected pancreatic can-
cer, with half receiving adjuvant gemcitabine plus placebo
and half receiving adjuvant gemcitabine plus GI-4000
[46].
3. Vaccines with Proteinsor Peptides
The use of proteins or peptides to stimulate a speciﬁc
immune response against cancer has long been investigated
andcoversabroadspectrumofpossibilitiesemployingsingle
agents or combinations of proteins, heat-shock proteins
(HSPs) [47], peptides and agonist peptides [48–51], anti-
idiotype antibodies [52, 53], and fusion proteins [54]. These
protein- or epitope-based vaccines have 2 main advantages
over the use of tumor cells or lysates: (a) production, storage,
and distribution are faster and more cost-eﬀective, and (b)
the identiﬁcation and administration of TSAs is preferable
since tumor-cell preparations mostly contain self-proteins
with no therapeutic beneﬁt and are potentially capable of
generating an autoimmune response. On the other hand,
this approach has certain drawbacks: (a) ﬁrst is the weak
immunogenicity of a single protein or, especially, a single
epitope; (b) tumors can easily escape immune recognition
through antigen mutation or loss; (c) their use is HLA-
restricted (mainly for epitope-based vaccines) and limited
to a subset of patients (usually HLA-A2+); (d) they have
a poor ability to induce balanced activation of CD4 and
CD8 subsets, which is thought to be essential for eﬀective,
long-lasting antitumor immunity. To date, in fact, most
epitope-based vaccines induce HLA-A2-restricted responses
that eﬃciently kill tumor cells but are characterized by
a limited lifespan in the absence of CD4 helper T cells.
Protein-based vaccines are capable of generating stronger
CD4 responses (MHC class II-restricted), but at the cost of
less eﬀective induction of CTLs [55, 56]. Most of the issues
describedabovecouldbeeasilyovercomebytheuseoflonger
peptides or the combination of several diﬀerent epitopes in
the same vaccine, while the relatively poor immunogenicity
of peptides could necessitate that they be administered with
adjuvants or loaded onto DCs [57, 58].
The use of speciﬁc proteins or peptides as targets for
immunotherapy clearly requires a careful choice of the
targeted TAAs and their epitopes, involving knowledge of
theirstructuralandfunctionalcharacteristics.Single-peptide6 Journal of Biomedicine and Biotechnology
epitopes composed of 8 to 10 amino acids are able to
induce a CTL response by binding to MHC class I molecules
expressed on APCs. Each epitope is composed of conserved
anchor residues (mostly at position 2 and the C-terminal
position)neededtobindtothecleftofMHCImoleculesand
residues that are speciﬁc for T-cell recognition. Theoretically,
changes in the former do not aﬀect the speciﬁcity of the
latter, and they have been used as a strategy to increase
the immunogenicity of several diﬀerent epitopes (agonist
epitopes) [38, 41, 42, 50, 59]. Furthermore, the ideal TAA
should be widely expressed in diﬀerent tumor types and also
play a central role in oncogenic processes or in cancer cell
survival, to avoid immune escape by mutations or loss of
antigens by tumor cells.
Identiﬁcation of novel TAAs can be achieved through 2
experimental processes: direct immunology (starting from
patient-derived autologous tumor-speciﬁc CTL clones spe-
ciﬁc for an unknown epitope) and reverse immunology
(starting from a predicted epitope). The former has been
used since the discovery of the ﬁrst tumor-speciﬁc CTL
epitope, MAGE-1 [60]. Direct immunology is further sub-
divided into genetic or biochemical approaches. Brieﬂy,
in the genetic approach, a patient-derived CTL clone is
screened by using target cells transfected with tumor-
derived cDNA libraries. Subsequently, the increased release
of cytokines in the supernatant due to the recognition
by the tumor-speciﬁc CTL clone allows one to select
the cells that contain the antigen-encoding cDNA; these
are then subcloned and rescreened to ﬁnally identify the
cDNA that encodes the speciﬁc antigen. The biochemical
approach consists of the puriﬁcation of peptides eluted
from MHC class I molecules of antigen-expressing cells
by high-performance liquid chromatography fractionation.
Antigen-negative target cells expressing the appropriate HLA
molecule are used to load these peptides and tested for
CTL recognition. Positive fractions are analyzed by mass
spectrometry to identify the amino acid sequence of the
epitope recognized by CTLs [61]. The need for expensive
specialized equipment, plus the labor-intensive method,
probablyaccountsfortheincreasinguseofreverseimmunol-
ogy. Over the years, a growing understanding of HLA-
speciﬁcpeptide-bindingmotifshasledtothedevelopmentof
several computer algorithms for amino acid sequences with
predicted binding capacity. Reverse immunology consists
of two diﬀerent phases: in the epitope prediction phase,
proteins are analyzed for the presence of potential epitopes
by the use of prediction algorithms. Subsequently, in the
epitope validation phase, the candidate peptides are tested by
binding and stability assays in vitro. Nevertheless, diﬀerences
betweentheprocessingmachineryinnormalandtumorcells
might be liable for the lack of activity against tumor cells
of several CTLs raised against high-aﬃnity binding TAAs
[62]. Nowadays, indeed, the most recent algorithms also take
into account the proteasomal processing and transporters
associated with antigen processing- (TAP-)translocation, 2
other fundamental processes in the antigen-presentation
pathway. Despite many eﬀorts, the use of epitope-based
vaccines has not advanced beyond phase I or II clinical trials,
probably due to the drawbacks described above. To date,
the best results have been achieved with the use of fusion
protein- or HSP-based vaccines.
Provenge (sipuleucel-T, Dendreon Corporation) is in
late-stage development for the treatment of mHRPC.
Sipuleucel-T is an immunotherapy product designed to
stimulate T-cell immunity against prostatic acid phosphatase
(PAP). It consists of autologous APCs isolated by leuka-
pheresis, cultured with a PAP-GM-CSF fusion protein, and
reinfused into the patient. The time from apheresis to
infusion of ﬁnal product is approximately 48 hours. The
eﬃcacy of Provenge was evaluated in 2 randomized, double-
blind, placebo-controlled phase III clinical trials (D9901
and D9902A) [7, 8]. D9901 enrolled 127 patients with
asymptomatic mHRPC, who were randomly assigned 2:1
to receive 3 infusions of Provenge (n = 82) or placebo
(n = 45) every 2 weeks. Enrollment in D9902A was stopped
at 98 patients after D9901 showed encouraging results in
terms of disease progression, and the study was amended
to become D9902B (IMPACT), enrolling 512 patients with
OS as the primary endpoint. An integrated analysis of 225
patients in D9901 and D9902A (147 in the vaccine arm
and 78 in the placebo arm) demonstrated a survival beneﬁt
for patients treated with Provenge versus placebo (23.2
months versus 18.9 months, resp.), with a 33% reduction
in the risk of death. The only immunological data to
emerge from these studies are limited to the correlation
between the upregulation of CD54 molecules on the cell
surface of sipuleucel-T-treated APCs and OS, whereas no
data are available about a speciﬁc immune response against
PAP. At the American Urological Association 2009 Annual
Meeting, Dendreon Corporation announced that the phase
III IMPACT clinical trial had met its primary endpoint
of signiﬁcantly improving OS by 4.1 months compared to
placebo {25.8 months versus 21.7 months, respectively, P =
.032, HR = 0.775 [95% CI: 0.614, 0.979]}.T h eU . S .F o o d
and Drug Administration (FDA) will respond to the existing
Dendreon’s amended Biologics License Application (BLA)
forthelicensingofProvengeinmenwithmetastaticcastrate-
resistant prostate cancer (CRPC) by May 2010. If approved,
Provenge will be the ﬁrst active cellular immunotherapy to
decisively demonstrate a survival beneﬁt for cancer patients.
Oncophage(vitespen,Antigenics),anautologoustumor-
derived HSP gp96 peptide complex, has been evaluated in
2 phase III clinical trials in stage IV melanoma patients
and in renal cell carcinoma (RCC) patients at high risk of
recurrence after nephrectomy [9, 10]. Oncophage consists
of a puriﬁed preparation of the HSP gp96 from tumor.
HSPs are noncovalently bound to peptides derived from
self- and tumor-speciﬁc proteins. Immunization with gp96
peptide complexes leads to their uptake by DCs through
CD91 (an HSP receptor) and stimulation of cognate T cells.
In the ﬁrst phase III clinical trial, 322 patients with stage IV
melanoma were randomized 2:1 to receive Oncophage or
a treatment of the physician’s choice. The ﬁrst 4 injections
were administered weekly and subsequent injections were
given every other week. Results from this trial suggested a
survival beneﬁt in the subpopulation of patients with M1a
or M1b disease who were able to receive 10 or more doses
of vaccine. In the second phase III trial of 818 patientsJournal of Biomedicine and Biotechnology 7
with postnephrectomy RCC, no diﬀerence in recurrence-
free survival or OS was observed between patients receiving
Oncophage versus no treatment, although a trend toward a
decrease in recurrence-free survival was reported in stage I
or II disease in the experimental arm.
In a prospective randomized multicenter phase III trial,
185 patients with locally advanced stage III or stage IV
melanoma were randomized to receive high-dose (HD) IL-
2 alone (94 patients) or a synthetic peptide from the gp100
melanoma-associated antigen [gp100:209-217(210M)] plus
an adjuvant (Montanide ISA) followed by HD IL-2 (91
patients). Overall response rate (RR, 22.1% versus 9.7%,
P = .0223) and progression-free survival (PFS) (2.9 months
versus 1.6, P = .0101) were signiﬁcantly improved in the
experimental arm compared with the HD IL-2 arm, respec-
tively. Median OS was 17.6 months in the HD IL-2 + vaccine
arm versus 12.8 in the HD IL-2 alone arm (P = .0964) [11].
Stimuvax (BLP25 liposome vaccine, L-BLP25, Onco-
thyreon partnered with Merck KGaA) is a cancer vac-
cine designed to induce an immune response against the
extracellular core peptide of MUC1, a type I membrane
glycoprotein widely expressed on many tumors (i.e., lung
cancer, breast cancer, prostate cancer, and colorectal cancer).
Stimuvax consists of MUC1 lipopeptide BLP25 [STAP-
PAHGVTSAPDTRPAPGSTAPPK(Pal)G], an immunoadju-
vant monophosphoryl lipid A, and three lipids (cholesterol,
dimyristoyl phosphatidylglycerol, and dipalmitoyl phos-
phatidylcholine), capable of enhancing the delivery of the
vaccine to APCs.
A randomized phase IIB clinical trial evaluated the eﬀect
of Stimuvax on survival and toxicity in 171 patients (88 in
the L-BLP25 arm and 83 in the best supportive care arm
(BSC)) with stage IIIB and IV nonsmall-cell lung cancer
(NSCLC), after stable disease or response to a ﬁrst-line
chemotherapy [12]. Median OS was 17.4 months in the L-
BLP25 arm and 13.0 months in the BSC arm, respectively,
with a nonsigniﬁcant improvement of 4.4 months in the
experimental arm (P = .112). T-cell proliferation assays
were conducted on 78 of 88 patients enrolled in the L-BLP25
group, before and after immunization. Sixteen patients
showed a MUC1-speciﬁc T-cell response (only two with a
locoregional stage IIIB disease). No severe toxicities were
reported. After a median follow-up of 53 months, updated
survival data reported a median OS of 30.6 months in
the Stimuvax arm versus 13.3 months in the BSC arm, in
the subgroup of patients with locoregional stage IIIB (65
patients, of whom 35 were randomized to the vaccine arm
and 30 were randomized to the BSC arm) (P = .09) [63].
Although nonsigniﬁcant, considering the magnitude of the
diﬀerence and the prolonged follow-up, these results suggest
a signal of eﬃcacy for the vaccine.
Based on these data, Merck is currently conducting three
large phase III clinical trials of Stimuvax. START (Stimulat-
ing Targeted Antigenic Responses To NSCLC) is a double-
blind,placebo-controlled,randomized,multicenterphaseIII
clinical trial that will enroll patients with unresectable stage
IIIA or IIIB NSCLC, after stable disease or response to a
platinum-based chemo-radiotherapy. This study will involve
more than 1,300 patients.
The INSPIRE study (Stimuvax trial In Asian NSCLC
Patients: stimulating Immune REsponse) will enroll approx-
imately 420 patients with unresectable stage III NSCLC
across China, Hong Kong, South Korea, Singapore, and Tai-
wan. STRIDE (STimulating immune Response In aDvanced
brEast cancer) is a randomized, double-blind, controlled,
multicenter Phase III study designed to evaluate the eﬃcacy
of Stimuvax, in combination with hormonal therapy, in
patients with inoperable, locally advanced, recurrent, or
metastatic breast cancer.
4. Vaccine with Tumor Cellsor
Tumor-Cell Lysates
Theoretically, tumor-cell vaccines have at least 3 advantages
over the single-target approaches discussed above in terms
of eliciting an immune response: (a) diﬀerent and unknown
antigens can be targeted at the same time; (b) the immune
response is not HLA-restricted; (c) the variety of both
MHC class I and class II epitopes processed is likely to be
able to stimulate both an innate (NK cells, macrophages,
and eosinophils) and adaptive (CD8+ and CD4+ T cells)
response.
The ﬁrst important distinction is between vaccines using
autologous (patient-speciﬁc) or allogeneic (nonpatient-
speciﬁc) tumor cells. Second, these cells may be unmodiﬁed,
modiﬁed for expression of MHC, costimulatory molecules,
or cytokines, or used in combination with adjuvants such as
GM-CSF and Bacille Calmette-Guerin (BCG). Third, these
cells can be used in the form of tumor-cell lysates [64].
The mechanism for priming na¨ ıve T cells in response
to whole-cell or lysate vaccination is still unclear. Tumor
antigens are probably phagocytosed by DCs and cross-
presented to CD8+ cells by MHC class I molecules. In some
models, a CD4+ response seems to be required for eﬀective
tumor rejection [65, 66]. A mesothelin-speciﬁc CD8+ T
cell response has been shown in a clinical trial employing
vaccination with GM-CSF-secreting pancreatic cancer cell
lines.Theresultsofthisstudyprovidetheﬁrstdirectevidence
that a cross-priming mechanism mediated by professional
APCs is involved in a postvaccination induction of CD8+ T
cell response [51].
In the past 20 years, several diﬀerent vaccines derived
from whole tumor cells or tumor-cell lysates have been
evaluated in preclinical models and clinical trials. OncoVAX
(Vaccinogen) is composed of autologous irradiated tumor
cells, with or without BCG as an adjuvant. In a multicenter
phase III clinical trial, 254 patients with stage II and III
coloncancerwererandomlyassigned,aftercurativeresection
for primary tumor, to receive OncoVAX or no adjuvant
treatment [13]. The 5.8-year median follow-up showed a
20.4% reduction in risk of disease progression in patients
receiving OncoVAX compared to the control group. Analysis
by stage showed no signiﬁcant beneﬁt of OncoVAX in stage
III disease, whereas a statistically signiﬁcant improvement
in recurrence-free survival in stage II was reported, with
a 41.4% reduction in relative risk of disease progression
(P = .018) in the OncoVAX arm. The OS rate for the
OncoVAX-treated group was higher compared to control,8 Journal of Biomedicine and Biotechnology
with an 11.1% and a 33.3% relative risk reduction in all
patients and stage II patients, respectively [14]. Besides
the clinical data and a prospective study of medical and
economic beneﬁts, the only immunological mechanism
proposed by the authors was the presence of a signiﬁcant
delayed cutaneous hypersensitivity response to tumor cells
after the third and fourth OncoVAX treatments (which lack
BCG), as a measure of the immugenicity of the treatment,
potentially correlated with long-term survival [15].
Reniale (LipoNova) is a vaccine designed to treat RCC. It
is based on a lysate of autologous tumor cells, preincubated
with IFN-γ to increase the antigenicity of these cells, and
tocopherol acetate to protect cell membranes during the
incubation process. A randomized, open-label, multicenter
phase III clinical trial compared adjuvant treatment with
Reniale after radical nephrectomy versus radical nephrec-
tomy alone in nonmetastatic RCC (pT2-3b, pN0-3, M0)
[16]. Prior to surgery, 558 patients at 55 institutions in
Germany were enrolled in the trial and were randomized
to receive 6 s.c. vaccinations at 4-week intervals, or no
adjuvant therapy (control group). The intention-to-treat
(ITT) population consisted of 379 patients in the primary
analysis (177 patients in the vaccine group and 202 patients
in the control group). Progression-free survival at 5 years for
patients at all tumor stages was 77.4% in the Reniale group
and 67.8% in the control group (P = .0204). Interestingly,
patients with a higher risk (T3 subgroup) showed greater
beneﬁt from adjuvant treatment with Reniale, with a 5-
year PFS of 67.5% in the vaccine group and 49.7% in the
control group. A secondary ITT analysis on 477 patients
(233 patients in the Reniale group and 244 patients in the
control group) showed a statistically signiﬁcant advantage in
the experimental arm in terms of PFS (P = .0476); there
was no statistically signiﬁcant diﬀerence in OS between the
2a r m s( P = .1185). However, a per-protocol analysis of
352 patients revealed a statistically signiﬁcant increase in PFS
(P = .024) and OS (P = .0356) in the vaccine arm [17]. No
immunological data from this study have been reported.
GVAX for prostate cancer (Cell Genesys) is an allogeneic
vaccine composed of 2 irradiated human prostate cancer cell
lines, LNCaP and PC-3, modiﬁed by ex vivo transduction
with an adenoassociated viral vector encoding the human
GM-CSF gene. A preclinical study has demonstrated that
s.c. administration of these cells invokes a local immune
response, characterized by a local inﬁltration of neutrophils,
CD4+ T cells, and apoptotic cells. The irradiated tumor cells
persist and secrete high levels of GM-CSF at the injection
site for >21 days. Theoretically, secretion of GM-CSF by
allogeneic tumor cells improves the antigen presentation
of TSAs and TAAs through recruitment and maturation
of DCs at the site of immunization. DCs then migrate to
draining lymph nodes and activate antigen-speciﬁc CD4+ T
cells, characterized by the production of both Th1 and Th2
cytokines. Moreover, DCs may eﬃciently capture apoptotic
tumor cells and cross-present multiple TAAs on MHC
class I molecules for recognition by host CD8+ T cells, as
demonstrated by the ability of GM-CSF-secreting tumor
cells to generate T-cell responses to multiple TAAs capable
of targeting antigenically related but distinct tumors [67].
Based on encouraging clinical and immunological responses
in 5 phase I/II clinical trials with nearly 200 prostate cancer
patients [68–70], 2 phase III trials were initiated. VITAL-
1 completed patient accrual in 2007, enrolling 626 patients
with mHRPC randomized to receive GVAX as monotherapy
for up to 6 months or standard docetaxel chemotherapy. The
primary endpoint of the trial was improvement in OS. In
2008, Cell Genesys terminated the trial based on the results
of a futility analysis conducted by the study’s Independent
Data Monitoring Committee (IDMC), which indicated a
<30% chance of meeting the primary endpoint. VITAL-
2 was a phase III trial designed to compare GVAX plus
docetaxel versus docetaxel alone in mHRPC. The primary
endpoint of VITAL-2 was also improved in OS. The trial
was initiated in 2005 and enrolled 408 patients. In 2008,
Cell Genesys announced its decision to terminate VITAL-
2, as recommended by a safety review in which the IDMC
reported an imbalance in deaths between the 2 treatment
arms (67/114 deaths in the GVAX plus docetaxel arm and
47/114 deaths in the docetaxel-alone arm). In this case,
despite encouraging preclinical and immunological data,
GVAX failed to meet the deﬁned endpoints of both phase III
clinical trials [6].
Further clinical trials, employing GVAX cancer
immunotherapies, are underway and include pancreatic
and breast cancers. A randomized three-arm clinical trial is
currently evaluating the eﬃcacy and toxicity of GVAX for
pancreatic cancer (GM-CSF secreting allogeneic pancreatic
cancer vaccine) administered either alone or in combination
with either a single intravenous dose or daily metronomic
oral doses of cyclophosphamide for the treatment of patients
undergoing chemotherapy and radiation therapy for stage I
or II disease, surgically resectable.
Recently, studies of combination therapies of GVAX vac-
cine and CTLA-4-blocking antibodies have shown activity in
melanoma and ovarian carcinoma, representing a potential
new strategy to enhance vaccine-mediated antitumor eﬀects
[71].
5.DNA andRNA Vaccines
DNA-based vaccines are a recently developed strategy that
has proven capable of activating strong immunity against
weak TAAs. Several approaches have been developed and
evaluated for enhancing the potency of DNA-based vac-
cines, including improved delivery systems (Gene Gun,
cationic liposomes) [72, 73], simultaneous administration
of cytokines (GM-CSF or IL2) [74], and the use of separate
plasmids encoding nonself-antigens (i.e., hepatitis B surface
antigen) [75]. The immunogenicity of DNA-based vaccines
can also be enhanced by various modiﬁcations of plasmid-
encoded antigens [76, 77].
Recently, several phase I/II clinical trials employing
DNA-based vaccines targeting diﬀerent TAAs (i.e., PSA,
PAP, gp100, CEA, hsp65) have been conducted in patients
with prostate cancer [78, 79], melanoma [80, 81], colorectal
cancer [75], and head and neck carcinomas [82]. In all
these trials, DNA-based vaccines were administered either asJournal of Biomedicine and Biotechnology 9
monotherapy or in association with diﬀerent delivery sys-
tems and adjuvants. In terms of immune response, most of
thesetrialsshowedalowimmunogenicityofTAAs.Thesmall
sample size of these phase I/II studies precludes achieving a
statistical correlation between development of an immune
response and clinical outcomes in vaccinated patients. Evi-
dence of clinical beneﬁt must be evaluated in larger studies.
mRNA-based gene transfer vaccines are another attrac-
tive immunotherapeutic approach to cancer treatment [83,
84]. This method, based primarily on transient transfection
of nondividing cells, is regarded as pharmaceutically safe
because the transfected mRNA does not integrate into the
host genome [85]. In addition, high transfection eﬃciency
can be achieved by electroporation [86, 87]. mRNA, which
can be eﬀectively overexpressed in target cells, is generated
by in vitro transcription from a bacteriophage promoter-
equipped plasmid DNA. It is composed of a cap structure
at the 5  end, the coding RNA for target antigen, and a tail of
poly-adenosine(polyAtail)[88].Thetargetantigenusedcan
be a single peptide PSA [89]o rC E A[ 90], allogeneic cancer
cell lines [18, 91, 92], or autologous tumor mRNA [93].
The mRNA-based vaccine containing the mRNA-coding
TAA is transfected into DCs and translated into proteins.
After protein processing, the antigen can be loaded on
MHC molecules for antigen presentation, thus activating an
antigen-speciﬁc CTL response [94].
Clinical trials have been performed employing mRNA-
transfected DCs or injecting mRNA directly into patients
with prostate cancer [18, 89, 95], RCC [96], ovarian cancer
[97], lung cancer, breast cancer [90], pediatric brain cancer
[98], neuroblastoma [99], and melanoma [100, 101]. A
phase I clinical trial was performed using PSA-mRNA-
transfected DCs in patients with metastatic prostate cancer
[89]. When the eﬀects of repeated vaccinations with PSA-
mRNA-transfected DCs were examined, the results demon-
stratedthatthevaccinewasabletoincreasePSA-speciﬁcCTL
responses.
In a phase I/II clinical trial in androgen-resistant prostate
cancer, patients were vaccinated with DCs transfected with
mRNA from 3 allogeneic prostate cancer cell lines (DU145,
LNCaP, and PC-3) [18]. Twelve of 19 patients showed
speciﬁc T-cell responses; 10 of those 12 had a positive
response in IFN-γ by ELISPOT assay and 9 had a speciﬁc
T-cell proliferation response. Two CD8+ CTL clones were
generated from a patient who showed a positive response in
both the ELISPOT and proliferation assay. The CTL clones
demonstrated speciﬁc killing of tumor mRNA-transfected
DCs and PC-3 cells. Of the 19 patients on-study, 11 showed
stable disease and 10 developed speciﬁc T-cell responses;
only 2 of 8 patients with disease progression showed T-cell
responses. These results demonstrate a correlation between
immune response and clinical response.
In another clinical trial, patients with metastatic RCC
received a vaccine consisting of DCs transfected with total
R N Ae x t r a c t e df r o mc l e a rc e l lc a r c i n o m a ,w i t ho rw i t h o u t
DAB389IL2 prevaccination [97]. The results showed a sig-
niﬁcant increase in the frequency of tumor-speciﬁc CD4+
and CD8+ T cells as well as a decrease in Treg frequency.
This trial demonstrated that mRNA-transfected DCs can
increase immune response, and that this immune response
in combination withdepletion of Tregs canhave a synergistic
eﬀect on antitumor immunity.
6. Conclusions
The promising results of recent phase II/III clinical trials
may herald a new era for cancer vaccine immunotherapy.
However, in spite of exciting improvements in the activity
and eﬃcacy of various vaccine platforms, including objective
response,disease-freesurvival,progression-freesurvival,and
overall survival, there is still much to learn about the
immunological mechanisms by which these results can be
improved. Further research is required to improve our
understanding of CTL antigen-speciﬁc activation, decreased
Treg numbers and functionality, NK activation, antigen
cascade, and the impact of tumor escape.
A paradigm shift is necessary in order to improve
the design of immuno-oriented clinical trials, increase
understanding of the balance between proinﬂammatory and
immunosuppressive responses in antitumor immunity, and
deﬁne new criteria for the immunological evaluation of
antitumor activity and clinical outcomes. Such knowledge
would not only improve the eﬃcacy of cancer vaccines but
would help to guide decisions regarding patient selection,
vaccine scheduling, and the combination of vaccines and
other treatment modalities such as surgery, radiotherapy,
chemotherapy, and targeted therapy.
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